Forum Financial Management LP Buys Shares of 2,065 Natera, Inc. (NASDAQ:NTRA)

Forum Financial Management LP bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,065 shares of the medical research company's stock, valued at approximately $327,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Gordian Capital Singapore Pte Ltd raised its position in shares of Natera by 59.7% during the 4th quarter. Gordian Capital Singapore Pte Ltd now owns 13,084 shares of the medical research company's stock worth $2,071,000 after buying an additional 4,891 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Natera during the fourth quarter worth approximately $2,941,000. Focus Partners Advisor Solutions LLC acquired a new stake in Natera in the fourth quarter worth approximately $227,000. Worldquant Millennium Advisors LLC boosted its stake in Natera by 55.0% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 6,331 shares of the medical research company's stock valued at $1,002,000 after purchasing an additional 2,247 shares in the last quarter. Finally, Vident Advisory LLC boosted its stake in Natera by 3.6% during the 4th quarter. Vident Advisory LLC now owns 7,060 shares of the medical research company's stock valued at $1,118,000 after purchasing an additional 244 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Stock Down 1.2%

NASDAQ NTRA traded down $1.93 during trading on Friday, reaching $156.12. 2,767,726 shares of the company's stock were exchanged, compared to its average volume of 1,405,031. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The company's fifty day simple moving average is $149.91 and its 200-day simple moving average is $158.35. The firm has a market capitalization of $21.32 billion, a PE ratio of -88.70 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period last year, the company posted ($0.56) earnings per share. Sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on NTRA shares. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Morgan Stanley boosted their target price on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average price target of $182.12.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 6,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the sale, the insider now directly owns 143,768 shares of the company's stock, valued at $20,600,516.72. This trade represents a 4.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. This represents a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,436 shares of company stock valued at $22,019,079 in the last quarter. Company insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.